In the RESONATETM trial of single-agent ibrutinib in patients with R/R CLL, which had a comparable percentage of high-risk patients (32% with del17p, 51% with TP53 mutation; 86% considered high risk in the ibrutinib arm), the cumulative ORR for ibrutinib at the 6-year follow-up was 91% [14], and in a phase 2 study with high-risk patients (63% with del17p and/or TP53 mutation), the ORR for ibrutinib was 96% at a follow-up of 6 months [15]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.